Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

February 19, 2024

Study Completion Date

February 19, 2024

Conditions
Bacteremia Sepsis
Interventions
DIAGNOSTIC_TEST

Resistell AST

The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.

Trial Locations (1)

1011

Institut de microbiologie CHUV R , Suisse +41 21 314 4056, Lausanne

All Listed Sponsors
collaborator

Innosuisse - Swiss Innovation Agency

OTHER

lead

Resistell AG

INDUSTRY